Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/30638
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLim, Hui Yin-
dc.contributor.authorBurrell, Louise M-
dc.contributor.authorBrook, Rowena-
dc.contributor.authorNandurkar, Harshal H-
dc.contributor.authorDonnan, Geoffrey A-
dc.contributor.authorHo, Prahlad-
dc.date2022-
dc.date.accessioned2022-08-02T06:42:40Z-
dc.date.available2022-08-02T06:42:40Z-
dc.date.issued2022-07-14-
dc.identifier.citationJournal of personalized medicine 2022; 12(7): 1140en
dc.identifier.issn2075-4426
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/30638-
dc.description.abstractCardiovascular disease remains the leading cause of death in the era of modern medicine despite major advancements in this field. Current available clinical surrogate markers and blood tests do not adequately predict individual risk of cardiovascular disease. A more precise and sophisticated tool that can reliably predict the thrombosis and bleeding risks at an individual level is required in order for clinicians to confidently recommend early interventions with a favorable risk-benefit profile. Critical to the development of this tool is the assessment and understanding of Virchow's triad and its complex interactions between hypercoagulability, endothelial dysfunction and vessel flow, a fundamental concept to the development of thrombosis. This review explores the pathophysiology of cardiovascular disease stemming from the triad of factors and how individualized risk assessment can be improved through the multimodal use of tools such as global coagulation assays, endothelial biomarkers and vessel flow assessment.en
dc.language.isoeng
dc.subjectVirchow’s triaden
dc.subjectcardiovascular diseaseen
dc.subjectendothelial markersen
dc.subjectglobal coagulation assaysen
dc.subjectrisk assessmenten
dc.titleThe Need for Individualized Risk Assessment in Cardiovascular Disease.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of personalized medicineen
dc.identifier.affiliationThe Melbourne Brain Centre, Royal Melbourne Hospital, University of Melbourne, Parkville, Melbourne, VIC 3010, Australia..en
dc.identifier.affiliationDepartment of Hematology, Northern Health, Epping, Melbourne, VIC 3076, Australia..en
dc.identifier.affiliationAustralian Centre for Blood Diseases, Monash University, Melbourne, VIC 3004, Australia..en
dc.identifier.affiliationDepartment of Medicine, Northern Health, University of Melbourne, Epping, Melbourne, VIC 3076, Australia..en
dc.identifier.affiliationMedicine (University of Melbourne)en
dc.identifier.affiliationNorthern Pathology Victoria, Northern Health, Epping, Melbourne, VIC 3076, Australia..en
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/35887637/en
dc.identifier.doi10.3390/jpm12071140en
dc.type.contentTexten
dc.identifier.orcid0000-0003-2455-3155en
dc.identifier.orcid0000-0003-1863-7539en
dc.identifier.orcid0000-0001-6324-3403en
dc.identifier.pubmedid35887637
local.name.researcherBurrell, Louise M
item.languageiso639-1en-
item.cerifentitytypePublications-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
crisitem.author.deptCardiology-
crisitem.author.deptGeneral Medicine-
crisitem.author.deptMedicine (University of Melbourne)-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

54
checked on Nov 4, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.